Covered recipient · General Payments record
MICHAEL JAMES DOWNING
Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$626.73
20 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $626.73 | 20 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Sage Therapeutics, Inc. | $325.00 | 5 |
| Janssen Pharmaceuticals, Inc | $104.32 | 4 |
| Alkermes, Inc. | $75.20 | 5 |
| ITI, Inc. | $39.20 | 2 |
| AbbVie Inc. | $37.62 | 2 |
| Teva Pharmaceuticals USA, Inc. | $26.15 | 1 |
| Indivior Inc. | $19.24 | 1 |
Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MICHAEL JAMES DOWNING
NPI 1639159346 · CMS profile ID 300554
Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry
DALLAS, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- MICHAEL JAMES DOWNING, NPI 1639159346, CMS profile ID 300554, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–20 of 20 matching records. This page contains 20 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1639159346?year=2023&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
20 matching records · $626.73 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–20 of 20.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $32.61 | 11/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988102165 | CMS |
| Teva Pharmaceuticals USA, Inc. | $26.15 | 11/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056789173 | CMS |
| Alkermes, Inc. | $13.92 | 11/08/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1022808419 | CMS |
| Indivior Inc. | $19.24 | 11/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034223069 | CMS |
| Alkermes, Inc. | $15.96 | 09/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1022808417 | CMS |
| Janssen Pharmaceuticals, Inc | $24.94 | 08/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988102155 | CMS |
| Alkermes, Inc. | $14.73 | 08/07/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1022808415 | CMS |
| ITI, Inc. | $25.55 | 06/28/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040517805 | CMS |
| Alkermes, Inc. | $15.42 | 06/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1022808413 | CMS |
| Sage Therapeutics, Inc. | $50.00 | 06/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017096065 | CMS |
| Sage Therapeutics, Inc. | $37.50 | 06/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017097227 | CMS |
| Sage Therapeutics, Inc. | $37.50 | 06/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017098319 | CMS |
| Sage Therapeutics, Inc. | $50.00 | 06/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017102035 | CMS |
| Sage Therapeutics, Inc. | $150.00 | 06/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1017104067 | CMS |
| Janssen Pharmaceuticals, Inc | $24.51 | 05/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988102187 | CMS |
| ITI, Inc. | $13.65 | 04/25/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040517795 | CMS |
| AbbVie Inc. | $15.42 | 03/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996737965 | CMS |
| Alkermes, Inc. | $15.17 | 02/22/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1022808411 | CMS |
| Janssen Pharmaceuticals, Inc | $22.26 | 02/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 988102175 | CMS |
| AbbVie Inc. | $22.20 | 01/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996737959 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $914,450.61 | 88 |
| PY2024 | Recipient | $2,949.66 | 2 |
| PY2024 | Principal investigator | $1,362,460.91 | 98 |
| PY2023 | Recipient | $59,611.81 | 14 |
| PY2023 | Principal investigator | $997,596.68 | 181 |
| PY2022 | Principal investigator | $897,046.39 | 115 |
| PY2021 | Principal investigator | $714,455.57 | 113 |
| PY2020 | Principal investigator | $1,352,717.69 | 219 |
| PY2019 | Recipient | $157,177.13 | 20 |
| PY2019 | Principal investigator | $1,373,636.72 | 268 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
88 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | ABBVIE INC. | $2,814.31 | 12/31/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS | Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202534351 |
| Principal investigator 1 | ABBVIE INC. | $600.00 | 12/31/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS | A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension | No dispute reported | 06/30/2026 | 1202534371 |
| Principal investigator 1 | ABBVIE INC. | $938.72 | 12/31/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies | No dispute reported | 06/30/2026 | 1202534373 |
| Principal investigator 1 | ABBVIE INC. | $852.28 | 12/31/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS | Multicenter, Open-label Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202534375 |
| Principal investigator 1 | Eli Lilly and Company | $12,116.14 | 12/16/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS LP | A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF BRENIPATIDE COMPARED WITH PLACEBO FOR REDUCTION IN RISK OF RELAPSE TO CIGARETTE SMOKING IN ADULTS (RENEW-SMK-1) | No dispute reported | 06/30/2026 | 1187882934 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $15,489.66 | 12/11/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916600 |
| Principal investigator 1 | ABBVIE INC. | $21,425.00 | 12/04/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202528908 |
| Principal investigator 1 | ABBVIE INC. | $7,198.10 | 12/04/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202528910 |
| Principal investigator 1 | ABBVIE INC. | $12,200.00 | 12/04/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LLC | Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder | No dispute reported | 06/30/2026 | 1202528912 |
| Principal investigator 1 | ABBVIE INC. | $12,032.00 | 12/04/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LLC | Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | No dispute reported | 06/30/2026 | 1202528914 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $19,885.16 | 11/14/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916598 |
| Principal investigator 1 | PFIZER INC. | $1,404.76 | 11/13/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | No dispute reported | 06/30/2026 | 1228818000 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 11/13/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | No dispute reported | 06/30/2026 | 1228818006 |
| Principal investigator 1 | ABBVIE INC. | $4,390.20 | 11/05/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202522625 |
| Principal investigator 1 | ABBVIE INC. | $18,449.60 | 11/05/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202522629 |
| Principal investigator 1 | PFIZER INC. | $2,928.00 | 10/30/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | No dispute reported | 06/30/2026 | 1228823438 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $32,914.48 | 10/17/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916596 |
| Principal investigator 1 | ABBVIE INC. | $15,663.78 | 10/09/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202514399 |
| Principal investigator 1 | ABBVIE INC. | $30,809.35 | 10/09/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202514401 |
| Principal investigator 1 | PFIZER INC. | $1,000.00 | 10/09/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS | No dispute reported | 06/30/2026 | 1228823443 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $422.00 | 09/26/2025 | Non-covered Recipient Entity Futuresearch Trials Of Dallas Llc | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067649 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $2,500.00 | 09/26/2025 | Non-covered Recipient Entity Futuresearch Trials Of Dallas Llc | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067651 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $1,413.60 | 09/26/2025 | Non-covered Recipient Entity Futuresearch Trials Of Dallas Llc | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067653 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $44,058.35 | 09/15/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916594 |
| Principal investigator 1 | ABBVIE INC. | $26,507.10 | 09/04/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LLC | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202509824 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,194.00 | 09/03/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223284943 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $5,000.00 | 08/29/2025 | Non-covered Recipient Entity Futuresearch Trials Of Dallas Llc | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067079 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $230.10 | 08/27/2025 | Non-covered Recipient Entity Futuresearch Trials Of Dallas Llc | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067077 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $36,986.55 | 08/13/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916592 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $10,800.00 | 08/06/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223283901 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,013.00 | 08/06/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223283903 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,025.00 | 08/06/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223283905 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,620.00 | 08/06/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223283907 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,038.00 | 08/06/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223283909 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,620.00 | 08/06/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS | TAK-861-3001 A Study to Evaluate the Efficacy and Safety of TAK-861 for the Treatment of Narcolepsy with Cataplexy | No dispute reported | 06/30/2026 | 1223283911 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 07/25/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228841087 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $60,742.75 | 07/23/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916590 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $4,488.00 | 07/11/2025 | Non-covered Recipient Entity Futuresearch Trials Of Dallas Llc | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248066987 |
| Principal investigator 1 | ABBVIE INC. | $4,317.30 | 07/02/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) | No dispute reported | 06/30/2026 | 1202494039 |
| Principal investigator 1 | ABBVIE INC. | $27,189.50 | 07/02/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202494041 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $50,885.81 | 06/13/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916588 |
| Principal investigator 1 | Eli Lilly and Company | $26,617.00 | 06/10/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS LP | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187881442 |
| Principal investigator 1 | ABBVIE INC. | $2,483.00 | 06/03/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202489815 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $39,528.05 | 05/16/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916586 |
| Principal investigator 1 | ABBVIE INC. | $13,691.60 | 05/07/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202483397 |
| Principal investigator 1 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $9,000.00 | 05/02/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | ITI-007-602 | No dispute reported | 06/30/2026 | 1242345705 |
| Principal investigator 1 | Eli Lilly and Company | $2,262.90 | 04/30/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS LP | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187882734 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $65,557.60 | 04/16/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916584 |
| Principal investigator 1 | ABBVIE INC. | $19,992.70 | 04/03/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202470249 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $33,600.46 | 03/24/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916582 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $1,158.30 | 03/12/2025 | Non-covered Recipient Entity Futuresearch Trials Of Dallas Llc | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067253 |
| Principal investigator 1 | Eli Lilly and Company | $38.25 | 03/10/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF NEUROLOGY LP | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187881766 |
| Principal investigator 1 | ABBVIE INC. | $5,484.70 | 03/07/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202459623 |
| Principal investigator 1 | Eli Lilly and Company | $223.77 | 03/05/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS LP | A PHASE 2, DOUBLE-BLIND, PROOF OF CONCEPT STUDY TO EVALUATE MAZDUTIDE COMPARED WITH PLACEBO IN PARTICIPANTS WITH ALCOHOL USE DISORDER | No dispute reported | 06/30/2026 | 1187881666 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.00 | 03/01/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646521 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.00 | 03/01/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646523 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $116.60 | 02/25/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646525 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 02/25/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646527 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 02/25/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646529 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.80 | 02/25/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646531 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $25,734.03 | 02/18/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916580 |
| Principal investigator 1 | ABBVIE INC. | $9,932.00 | 02/06/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine | No dispute reported | 06/30/2026 | 1202446943 |
| Principal investigator 1 | PFIZER INC. | $99.00 | 02/06/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1228859040 |
| Principal investigator 1 | PFIZER INC. | $626.50 | 02/06/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1228860049 |
| Principal investigator 1 | Eli Lilly and Company | $29,310.00 | 02/04/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS LP | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187881094 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 02/01/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646511 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 02/01/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646513 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.00 | 02/01/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646515 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.00 | 02/01/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646517 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.39 | 02/01/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646519 |
| Principal investigator 1 | Eli Lilly and Company | $5,160.06 | 01/31/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF NEUROLOGY LP | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187884088 |
| Principal investigator 1 | PFIZER INC. | $5,771.23 | 01/30/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | No dispute reported | 06/30/2026 | 1228860056 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $2,376.00 | 01/29/2025 | Non-covered Recipient Entity Futuresearch Trials Of Dallas Llc | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067583 |
| Principal investigator 1 | PFIZER INC. | $1,242.60 | 01/23/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | No dispute reported | 06/30/2026 | 1228859047 |
| Principal investigator 1 | Eli Lilly and Company | $794.28 | 01/21/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS LP | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187880009 |
| Principal investigator 1 | Eli Lilly and Company | $14,032.00 | 01/21/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS LP | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187882730 |
| Principal investigator 1 | Eli Lilly and Company | $2,200.18 | 01/20/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF NEUROLOGY LP | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187881764 |
| Principal investigator 1 | Axsome Therapeutics, Inc. | $8,017.77 | 01/14/2025 | Non-covered Recipient Entity FutureSearch Trials of Dallas LLC | A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms | No dispute reported | 06/30/2026 | 1199916578 |
| Principal investigator 1 | Lexicon Pharmaceuticals, Inc. | $1,941.30 | 01/14/2025 | Non-covered Recipient Entity Futuresearch Trials Of Dallas Llc | LX9211.1-204-DPN | No dispute reported | 06/30/2026 | 1248067581 |
| Principal investigator 1 | Eli Lilly and Company | $1,327.27 | 01/09/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF NEUROLOGY LP | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187883080 |
| Principal investigator 1 | Eli Lilly and Company | $4,760.88 | 01/09/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF NEUROLOGY LP | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1187883082 |
| Principal investigator 1 | Eli Lilly and Company | $68,123.00 | 01/07/2025 | Non-covered Recipient Entity FUTURE SEARCH TRIALS OF DALLAS LP | A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT | No dispute reported | 06/30/2026 | 1187883078 |
| Principal investigator 1 | Sage Therapeutics, LLC | $10,570.50 | 01/06/2025 | Non-covered Recipient Entity FUTURESEARCH TRIALS OF DALLAS LP | A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease | No dispute reported | 06/30/2026 | 1206580651 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 01/01/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646503 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $45.00 | 01/01/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646505 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.00 | 01/01/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646507 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.00 | 01/01/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646509 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.39 | 01/01/2025 | Non-covered Recipient Entity Future Search Trials Dallas Clinic | Phase II dose finding trial in monotherapy for MDD | No dispute reported | 06/30/2026 | 1220646533 |